Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …

The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for
thyroid cancer has significantly improved the understanding of the molecular pathogenesis …

Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …

The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated,
medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Thyroid cancer typically has a good outcome following standard treatments, which include
surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine …

Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is
generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such …